mRNA splicing variants: Exploiting modularity to outwit cancer therapy

Cancer Research

Volumn 73, Issue 17, 2013, Pages 5309-5314

  Dehm, Scott M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; B RAF KINASE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GEFITINIB; GEMCITABINE; IKAROS 6; IKAROS TRANSCRIPTION FACTOR; IMATINIB; MESSENGER RNA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 2B; PROTEIN AIMP2 DX2; PROTEIN BCL 2; PROTEIN BIM GAMMA; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; SURVIVIN; SURVIVIN 2B; TAXANE DERIVATIVE; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; PLASTICITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; REVIEW; RNA SPLICING; SPLICEOSOME; THERAPY RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENETIC VARIATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; RNA SPLICING;

EID: 84883483017     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0444     Document Type: Review

References (30)

1. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature 2012;489:101-8.
2. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010;24: 2343-64.
3. Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol Ther 2012;136:283-94.
4. Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol 2006;17(Suppl 10):x315-24. (Pubitemid 44542029)
5. Eblen ST. Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 2012;83:1063-72.
6. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl +leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006;103:14907-12. (Pubitemid 44527827)
7. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-8.
8. Fenstermaker RA, Ciesielski MJ. EGFR intron recombination in human gliomas: inappropriate diversion of V(D)J recombination? Curr Genomics 2007;8:163-70. (Pubitemid 46902206)
9. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, et al. EGFRvIII andDNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009;69:4252-9.
10. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011;1: 524-38.
11. Arjona D, Bello MJ, Rey JA. EGFR intragenic loss and gene amplification in astrocytic gliomas. Cancer Genet Cytogenet 2006;164:39-43. (Pubitemid 41820354)
12. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006;103:7817-22.
13. Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112:3847-55.
14. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110- 4.
15. Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, et al. Cancer-associated splicing variant of tumor suppressor AIMP2/ p38: pathological implication in tumorigenesis. PLoS Genet 2011;7:e1001351.
16. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009;113:4362-9.
17. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011;18:R183-96.
18. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castrationresistant prostate cancer. Cancer Res 2012;72:3457-62.
19. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73:483-9.
20. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011;71: 2108-17.
21. Li Y, Hwang TH, Oseth L, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012;31:4759-67.
22. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
23. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res 2011;17:3716- 26.
24. Scheper GC, Parra JL, Wilson M, Van Kollenburg B, Vertegaal AC, Han ZG, et al. The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol Cell Biol 2003;23: 5692-705. (Pubitemid 36951333)
25. Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R, et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013;32:2848-7.
26. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012;19:220- 8.
27. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14:185-93. (Pubitemid 46355578)
28. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007;67:2072-80. (Pubitemid 46424225)
29. Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012;11:847-59.
30. Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genetics 2011;27:196-205.